flutide 50 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 50 mikrog/ dose
flutide 125 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 125 mikrog/ dose
flutide 250 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 250 mikrog/ dose
flutide 50 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonspulver, dosedispensert - 50 mikrog/ dose
flutide 100 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonspulver, dosedispensert - 100 mikrog/ dose
flutide 250 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonspulver, dosedispensert - 250 mikrog/ dose
flutide 500 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonspulver, dosedispensert - 500 mikrog/ dose
spiriva respimat 2.5 mikrog
boehringer ingelheim international gmbh - tiotropiumbromid - inhalasjonsvæske, oppløsning - 2.5 mikrog
voriconazole fresenius kabi 200 mg
fresenius kabi norge as - vorikonazol - pulver til infusjonsvæske, oppløsning - 200 mg
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.